Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly replacing viral hepatitis as a leading cause of hepatocellular carcinoma (HCC) worldwide. MASLD-related HCC (MASLD-HCC) displays a distinctive and complex biological phenotype, particularly in terms of its immune microenvironment and response to immunotherapy, however, the related underlying mechanisms remain insufficiently investigated. Recent studies have suggested a crucial role of the gut microbiota in regulating hepatic inflammatory and immune responses during the malignant transformation from MASLD to HCC, known as the gut-liver axis. In this review, the dynamic alterations in the gut microbiome during MASLD-HCC initiation and development are summarized. The relevant mechanisms, including the gut–liver axis, hepatic immune reprogramming and microbial metabolite-induced signalling pathways, are discussed in this review. Moreover, several potential microbiota-targeted strategies for preventing or treating MASLD-HCC, including dietary intervention, probiotics, antibiotics, fecal microbiota transplantation, natural products and plant-derived bioactive compounds, are evaluated. Finally, challenges and future directions for basic and translational research in this field are discussed. Taken together, these findings suggest that the gut microbiota is a novel diagnostic biomarker and therapeutic target for MASLD-HCC management.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: